Ovarian Cancer pp 221-233 | Cite as

Biological Therapy with Oncolytic Herpesvirus

  • Fabian Benencia
  • George Coukos
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 622)

Oncolytic virus therapy refers to the biological therapy of tumors, using live viruses with relative tumor selectivity. Replication-restricted virus strains have been genetically engineered, which replicate selectively within tumor cells. Examples include replication-competent mutants of herpes virus, adenovirus, vesicular stomatitis virus, reovirus, and measles virus (2, 17, 37, Martuza, 2000; 56, 63). In particular, replication-competent recombinant HSV strains may offer distinct advantages in oncolytic therapy of epithelial tumors: (a) HSV is highly infectious to tumors of epithelial origin, resulting in high efficacy (70); (b) there is considerable redundancy in HSV receptors, which makes the loss of HSV receptors by tumors due to mutations less likely; (c) antiherpetic drugs are commercially available, which may be used clinically to control undesired side effects, should local or systemic spread of the virus occur; and (d) because of its large genome, HSV offers ample packaging opportunities – up to 30 kb – without affecting viral replication in cancer cells.


Vascular Endothelial Growth Factor Ovarian Carcinoma Herpes Simplex Virus Type Vascular Endothelial Growth Factor Level Epithelial Ovarian Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer 2008

Authors and Affiliations

  • Fabian Benencia
    • 1
  • George Coukos
    • 2
  1. 1.Department of Biomedical SciencesOhio UniversityAthens
  2. 2.Center for Research on the Early Detection and Cure of Ovarian CancerUniversity of PennsylvaniaPhiladelphia

Personalised recommendations